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Abstract
Failure of oligodendrocyte precursor cell (OPC) differentiation contributes signiﬁcantly to failed myelin sheath regeneration
(remyelination) in chronic demyelinating diseases. Although the reasons for this failure are not completely understood, several
lines of evidence point to factors present following demyelination that speciﬁcally inhibit differentiation of cells capable of
generating remyelinating oligodendrocytes. We have previously demonstrated that myelin debris generated by demyelination
inhibits remyelination by inhibiting OPC differentiation and that the inhibitory effects are associated with myelin proteins. In the
present study, we narrow down the spectrum of potential protein candidates by proteomic analysis of inhibitory protein fractions
prepared by CM and HighQ column chromatography followed by BN/SDS/SDS–PAGE gel separation using Nano-HPLC-ESI-
Q-TOF mass spectrometry. We show that the inhibitory effects on OPC differentiation mediated by myelin are regulated by
Fyn-RhoA-ROCK signalling as well as by modulation of protein kinase C (PKC) signalling. We demonstrate that pharmacological
or siRNA-mediated inhibition of RhoA-ROCK-II and/or PKC signalling can induce OPC differentiation in the presence of myelin.
Our results, which provide a mechanistic link between myelin, a mediator of OPC differentiation inhibition associated
with demyelinating pathologies and speciﬁc signalling pathways amenable to pharmacological manipulation, are therefore of
signiﬁcant potential value for future strategies aimed at enhancing CNS remyelination.
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Introduction
It is well established that cell populations in the adult CNS exist
which are able to give rise to cells of all major cell lineages includ-
ing neurons, oligodendrocytes and astrocytes (Alvarez-Buylla and
Lois, 1995; Horner et al., 2000; Nunes et al., 2003). Although the
ability of these cells to replace lost neurons is relatively poor their
ability to replace oligodendrocytes (and hence remyelinate demye-
linated axons) can be very efﬁcient in both experimental models
and sometimes in clinical disease (Patrikios et al., 2006; Patani
et al., 2007; Blakemore and Franklin, 2008). Remyelination in
the CNS is mediated by a multipotent adult stem/precursor cell
population traditionally referred to as oligodendrocyte precursor
cells (OPCs) (ffrench-Constant and Raff, 1986; Wolswijk and
Noble, 1989; Gensert and Goldman, 1997; Carroll et al., 1998;
Sim et al., 2002). Although remyelination can be efﬁcient it often
fails in clinical disease for reasons that are not fully understood
(Franklin, 2002). The chronic demyelination that follows is asso-
ciated with axonal loss, so providing a possible mechanism for
progressive disability in patients suffering from diseases in which
chronic demyelination occurs of which the most important is mul-
tiple sclerosis. Several lines of evidence both experimental
(Woodruff et al., 2004; Foote and Blakemore, 2005) and clinical
(Wolswijk, 1998, 2002; Chang et al., 2000; Totoiu and Keirstead,
2005; Kuhlmann et al., 2008) point to the failure of OPC differ-
entiation as a major cause of remyelination failure. Indeed, regu-
lation of OPC differentiation in remyelination represents an
attractive model for the more general stem cell medicine challenge
of inducing differentiation of repair cells from adult neural stem/
precursor cells.
A possible explanation for the failure of OPC differentiation in
multiple sclerosis is the presence of inhibitors within demyelinated
lesions. A number of potential inhibitors have been proposed
including axonal PSA-NCAM in chronically demyelinated lesions
(Charles et al., 2002), astrocytic hyaluronan (Back et al., 2005)
and notch-jagged (John et al., 2002) signalling, although these
are not always supported by functional studies in animals
models (Stidworthy et al., 2004). We have previously shown
that myelin debris accumulating in lesions as a result of demyeli-
nation exerts a powerful inhibitory effect on OPC differentiation
unless it is cleared by phagocytes (Kotter et al., 2006). With
ageing, the efﬁciency of myelin debris removal decreases (Ibanez
et al., 2004) and this may contribute to the impairment in OPC
differentiation that underlies the age-associated decline in remye-
lination efﬁciency (Sim et al., 2002; Woodruff et al., 2004).
In this study, we identiﬁed potential protein inhibitors by
column-chromatography based puriﬁcation of inhibitory fractions
followed by 3D gel electrophoresis and Nano-HPLC-ESI-Q-TOF
mass spectrometry. We explored the cell intrinsic mechanisms by
which myelin inhibits OPC differentiation in order to identify
pathways that can be pharmacologically modulated and hence
used as potential remyelination-enhancing therapies. We address
the hypothesis that myelin-mediated inhibition of OPC differenti-
ation is mediated by (i) Src-family (Fyn-1)–RhoA-ROCK-II signal-
ling or (ii) protein kinase C (PKC) pathway signalling. By assessing
the activation of key molecules of both pathways, we provide
evidence of a direct involvement of Src family kinase Fyn and
RhoA in mediating the inhibitory effects as well as a modulation
of PKC signalling. Our results demonstrate that inhibition of either
ROCK-II or PKC is able to induce OPCs differentiation in the pres-
ence of myelin thus providing a mechanism which could be of
signiﬁcant therapeutic value.
Materials and methods
Preparation and puriﬁcation of OPC
Primary cultures of OPCs were isolated from P0 to P2 neonatal Sprague-
Dawley rat forebrains following a standard protocol (McCarthy and
de Vellis, 1980) that we have adapted for our purposes (Syed et al.,
2008). In brief, hemispheres were stripped free of meninges, after a
digestion step the cells were plated into cell culture ﬂasks and mixed
glia cultures were grown for  10 days in DMEM medium supplemented
with 10% FCS at 37 C and 7.5% CO2. To remove the loosely attached
microglia, the ﬂasks were shaken for 1h at 260 r.p.m. on an orbital
shaker before being shaken at 260 r.p.m. overnight to dislodge the
loosely attached oligodendrocyte precursors. OPCs were further puri-
ﬁed from contaminating microglia by a differential adhesion step.
Subsequently, OPCs were plated onto polylysine (PLL)-coated or
substrate coated dishes. To maintain cells at an early precursor stage
PDGF-AA (Pepro Tech, Rocky Hill, NJ, USA) and FGF (Pepro Tech)
were added (10ng/ml) to SATOs medium. To induce differentiation,
cells were incubated in SATOs medium supplemented with 0.5% FCS.
The purity of each culture was monitored following OPC puriﬁcation
by immunocytochemistry and only cultures with 494% purity were
used. Minor contaminations of microglia, that can be detected by
isolectin staining and which amount to 4–5% of the cells, astrocytes
(detectable by GFAP) and ﬁbroblasts with distinct morphology and
which account for  1–2% of the cells, were present in the cultures.
Preparation of myelin membrane
substrates and myelin protein extracts
Myelin was puriﬁed by two rounds of discontinuous density gradient
centrifugation and osmotic disintegration (Norton and Poduslo, 1973).
Total brains of young Sprague-Dawley rats were homogenized
mechanically in ice-cold 0.32M sucrose using a mechanical blender
(Ultra-Turrax; IKA, T18 basic, Germany). Sucrose was dissolved in ster-
ile 2.5mM Tris/HCl, pH 7.0, to form 0.25, 0.32 and 0.88M solutions.
The homogenized brains were diluted to a ﬁnal 0.25M sucrose
solution and pelleted in an ultra-centrifuge (55000g,4  C, 15min).
The pellet was re-suspended in 0.88M sucrose solution and overlaid
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1h), the interface was collected and washed in 30ml of distilled
H2O (55000g,4  C, 10min). The pellet was re-suspended in
dH2O and incubated for 60min on ice for osmotic disintegration.
After centrifugation (55000g,4  C, 10min), the ﬂotation step was
repeated. The interface was collected and washed twice in dH2O
(55000g,4  C, 10min), and the pellet was stored at –80 C until iso-
lation of myelin protein extracts (MPEs).
To prepare MPE the pellets were resuspended in 1% N-octyl b-D-
glucopyranoside, 0.2M Sodiumphosphate pH 6.8, 0.1M Na2SO4 and
1mM EDTA and incubated at 23 C for 2h. Following an ultracentri-
fugation step (100000g,1 8  C, 30min) the supernatants were col-
lected and stored at –20 C until further usage (Kotter et al., 2006;
Syed et al., 2008).
Isolation of liver membrane fractions
Sucrose (0.85 and 1.23M) in 2.5mM Tris/HCl was prepared as
outlined above. The liver of a young adult Sprague-Dawley rat was
extracted and homogenized in 0.85M sucrose (using an Ultra-Turrax).
The homogenate was layered onto a 1.23M sucrose solution. After
centrifugation (100000g,4  C, 1h) the interface was collected and
washed in dH2O (55000g,4  C, 10min). Finally, the pellet was resus-
pended in an equal volume of 1  PBS containing 1% octyglucoside
and 1mM EDTA. After incubation at 25 C for 2h in a shaker the
sample was ultracentrifuged at 100000g for 30min and ﬁnally, the
supernatant was stored at –20 C until further use. The protein con-
centration was estimated by BCA assay (Pierce, Rockford, IL, USA)
(Kotter et al., 2006).
Chromatography column based
separation of inhibitory myelin
protein fractions
About 50ml of the MPE ( 1mg/ml) were ﬁltered through a 0.22m
Millipore membrane ﬁlter. The ﬁltrate was desalted and concentrated
using Amicon ultraﬁltration cell (Millipore, Billerica, MA, USA; mem-
brane diameter 44.5mm; cut off 10000Da) with 50mM sodium
acetate (pH4). This step was repeated three times to ensure that the
sample was maximally desalted. The concentrated and desalted
lysate was subsequently loaded on a CM column (Econo-Pac CM
cartridges, 1ml, Biorad, Hercules, CA, USA). Column chromatography
was performed using an FPLC System with a built in detector (Pharmacia
Fine Chemicals, GE Healthcare, Bucks. UK). The injection volume was
10ml; 50mM sodium acetate buffer containing 1% octlyglucoside
(mobile phase A) was used as washing buffer and 1M NaCl containing
1% octylglucoside (mobile phase B) was used as elution buffer. The
following chromatographic gradients were applied: 0% B for 15min,
0–70% B, hold with 70% B for 10min followed by a wash with A for
10min. The ﬂow rate used was 2ml/min, the fraction size 1ml/min and
sensitivity of the detector was 1U at a wavelength of 280nm.
The non-binding fractions and the binding fractions were pooled
together separately and assessed for inhibitory activity on OPC differ-
entiation using the in vitro substrate assay outlined below. Repeat
experiments demonstrated that the inhibitory effects on OPC differ-
entiation were associated with the nonbinding fraction of the CM
column.
To further eliminate proteins with non-inhibitory activity, the inhib-
itory non-binding fraction was concentrated and the buffer exchanged
to a 0.1M Tris–Cl buffer containing 1% octlylglucoside (pH 8). The
concentrate was subsequently loaded on an anion exchange EconoPac
High Q cartridge (1ml; Bio-Rad) and coupled to the FPLC system
(GE Healthcare UK Ltd, Little Chalfont, Buckinghamshire, UK).
0.1M Tris–Cl containing 1% octylglucoside was used as washing
buffer (Mobile phase A). The binding fraction was eluted using 1M
NaCl in 0.1M Tris–Cl containing 1% octylglucoside (Mobile Phase B).
The injection volume was 10ml. The reaction conditions were as fol-
lows: 0% B in 5min and 0–100% B in 10min, 100% B for 10min and
washing with A for 5min. The ﬂow rate was maintained at 2ml/min at
25 C. The detection wavelength was 280nm and sensitivity set at 1U.
The resulting binding and non-binding fractions were again pooled
separately. When tested for their inhibitory effects the inhibitory activ-
ity was associated with the binding fraction. The pooled binding
fractions were further concentrated and the buffer exchanged to a
buffer composed of 250mM 6-aminocaproic acid, 25mM Bis–Tris,
pH 7.0 using Amicon ultra centrifugal ﬁlter devices.
One dimensional electrophoresis:
BN-PAGE
60ml of puriﬁed inhibitory myelin protein fractions ( 2mg/ml) was
added to 10ml of G250 solution [5% (w/v) Coomassie G250 in
10mM 6-aminocaproic acid] and loaded onto the gel. BN-PAGE
(Wittig et al., 2006) was performed in a PROTEAN II xi Cell
(BioRad, Germany) using a 4% stacking and a 5–13% separating
gel. The gel buffer contained 250mM 6-aminocaproic acid, 25mM
Bis-Tris, pH 7.0; the cathode buffer 50mM Tricine, 15mM Bis-Tris,
0.05% (w/v) Coomassie G250, pH 7.0; and the anode buffer 50mM
Bis-Tris, pH 7.0. For electrophoresis, the voltage was set to 70V
for 2h, and was increased to 250V (10mA/gel) until the dye
front reached the bottom of the gel. BN-PAGE gels were cut
into small pieces of  1–3cm depending on the intensity of pro-
tein bands for the BN/SDS/SDS–PAGE three dimensional electropho-
resis (3DE).
Three dimensional electrophoresis:
BN/SDS/SDS–PAGE
The experimental procedures and advantages of BN/SDS/SDS–PAGE
(3DE) are summarized in Kang et al. (2008). Brieﬂy, 1–3cm gel pieces
from BN-PAGE were soaked for 2h in a solution of 1% (w/v) SDS and
1% (v/v) 2-mercaptoethanol. Gel pieces were then rinsed twice with
SDS–PAGE electrophoresis buffer [25mM Tris–HCl, 192mM glycine
and 0.1% (w/v) SDS; pH 8.3], then the gel pieces were placed onto
the wells. 2DE-SDS–PAGE was performed in PROTEAN II xi Cell using
a 4% stacking and a 6–13% separating gel for BN/SDS–PAGE (2DE).
Electrophoresis was carried out at 25 C with an initial current of 70V
(during the ﬁrst hour). The voltage was then set to 100V for the next
12h (overnight), and increased to 200V until the bromophenol blue
marker moved 17cm from the top of separation gel.
2DE gels were cut again into lanes and gel strips from each lane
were soaked for 20min in a solution of 1% (w/v) SDS and 1% (v/v)
2-mercaptoethanol. Gel strips were then rinsed twice with SDS–PAGE
electrophoresis buffer (25mM Tris–HCl, 192mM glycine and 0.1%
(w/v) SDS; pH 8.3), and were placed onto the wells of another
gel (3DE). SDS–PAGE was performed in PROTEAN II xi Cell using
a 4% stacking and a 7.5–17% separating gel. Electrophoresis
was carried out at 25 C with an initial current of 70V (during
the ﬁrst hour). Then, the voltage was set to 100V for the next 12h
(overnight), and increased to 200V until the dye front reached the
bottom of the gel. Colloidal Coomassie blue staining was used for
visualization.
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fraction with trypsin
The gel pieces of interest were cut into small pieces to increase surface
and collected in a 0.6ml tube. They were initially washed with 50mM
ammonium bicarbonate and then twice with 50% 50mM ammonium
bicarbonate/50% acetonitrile for 30min with occasional vortexing.
The washing solution was discarded at the end of each step.
100 microlitre of 100% acetonitrile was added to each tube to
cover the gel piece followed by incubation for at least 5min.
The gel pieces were dried completely in a Speedvac Concentrator
5301 (Eppendorf, Germany). Cysteines were reduced with a
10mM dithiothreitol solution in 0.1M ammonium bicarbonate pH
8.6 for 60min at 56 C. The same volume of a 55mM solution of
iodoacetamide in 0.1M ammonium bicarbonate buffer pH 8.6 was
added and incubated in darkness for 45min at 25 C to alkylate
cysteine residues. The reduction/alkylation solutions were replaced
by 50mM ammonium bicarbonate buffer for 10min. Gel pieces
were washed and dried in acetonitrile followed by Speedvac
concentration.
The dried gel pieces were re-swollen with 12.5ng/ml trypsin
(Promega, WI, USA) solution buffered in 25mM ammonium bicarbo-
nate. They were incubated for 16h (overnight) at 37 C. Supernatants
were transferred to new 0.6ml tubes, and gel pieces were extracted
again with 50ml of 0.5% formic acid/20% acetonitrile for 15min in a
sonication bath. This step was performed twice. Samples in extraction
buffer were pooled in a 0.6ml tube and evaporated in a Speedvac.
The volume was reduced to  10ml and 10ml water was added.
Protein identiﬁcation with Nano-HPLC-
ESI-Q-TOF mass spectrometry
LC-ESI-MS/MS analyses were carried out with the UltiMate 3000
system (Dionex Corporation, Sunnyvale, CA, USA) interfaced to the
QSTAR Pulsar mass spectrometer (Applied Biosystems, Foster City, CA,
USA). A nanoﬂow HPLC equipped with a reversed phase PepMap
C-18 analytic column (75mm 150mm) was used. Chromatography
was performed using a mixture of two solutions, A (0.1% formic acid
in water) and B (80% acetonitrile/0.85% formic acid in water), with a
ﬂow rate of 300 nl/min. First a linear gradient between 4% and 60%
B was run over 45min, then 90% B was used for 5min and 0% B for
25min. Peptide spectra were recorded over the mass range of m/z
350–1300, and MS/MS spectra were recorded under information
dependent data acquisition (IDA) over the mass range of m/z
50–1300. One peptide spectrum was recorded followed by three
MS/MS spectra on the QSTAR Pulsar instrument; the accumulation
time was 1s for peptide spectra and 2s for MS/MS spectra. The col-
lision energy was set automatically according to the mass and charge
state of the peptides chosen for fragmentation. Doubly or triply
charged peptides were chosen for MS/MS experiments due to their
good fragmentation characteristics. MS/MS spectra were interpreted
by the MASCOT software (mascot.dll 1.6b21; Matrix Science, London,
UK) in Analyst QS 1.1 (Applied Biosystems). Searches were done by
using the MASCOT 2.1 (Matrix Science, London, UK) against
Swissprot 53.3 and MSDB 20051115 database for protein identiﬁca-
tion. Searching parameters were set as follows: enzyme selected as
trypsin with a maximum of two missing cleavage sites, species limited
to mouse, a mass tolerance of 500ppm for peptide tolerance, 0.2Da
for MS/MS tolerance, ﬁxed modiﬁcation of carbamidomethyl (C) and
variable modiﬁcation of methionine oxidation and phosphorylation
(Tyr, Thr and Ser).
Immunocytochemistry
The pooled OPCs harvested as outlined above were seeded at a
density of 20000 cells per well into PLL-coated eight-well chamber
slides. Cells were differentiated for 48h and subsequently ﬁxed with
4% paraformaldehyde in PBS, permeabilized and blocked with 0.3%
Triton X-100 and 10% NGS. To assess the differentiation state of
OPCs the cells were incubated with O4 antibody (1:100; Millipore
Corporation, Billerica, MA, USA) for 1h in the presence of 0.1%
Triton X-100 and 2% NGS, washed, and incubated for another 1h
with the appropriate ﬂuorescent secondary antibody (Cy3-conjugated
antibody 1:100; Jackson Immuno Research, Suffolk, UK) and the nuclei
were stained using DAPI (Robinson and Miller, 1999; Syed et al.,
2008). It is important to note that permeabilization of cells results in
a punctate representation of the extracellular antigen O4 (Reynolds and
Weiss, 1993; Weiss et al., 1996; Syed et al., 2008). Under an Olympus
X51 ﬂuorescent microscope using a triple-ﬁlter we determined the per-
centage of O4-positive cells in relation to4100 DAPI-stained nuclei in
randomly selected eye ﬁelds for each experimental condition.
To establish the purity of our OPC cultures immunocytochemistry for
A2B5 (1:100; Millipore Corporation, Billerica, MA, USA) was performed
according to the same principles and the percentage of A2B5+ cells to
4100 DAPI-stained nuclei in randomly selected eye ﬁelds was deter-
mined. Only cell cultures with 494% A2B5+ cells were used for our
study. To assess the morphological phenotype of OPCs, A2B5+ cells
were categorized according to the following criteria: stage I: mono/bipo-
lar; stage II: multipolar, primary branched; stage III: multipolar, secondary
branched; stage IV: secondary branched cells with membranous processes.
qPCR for myelin basic protein versus
b-2-microglobulin
Total RNA of OPCs grown on PLL control or MPE substrates with
various concentrations (0.4mg MPE, 4mg MPE and 40mg MPE) was
harvested after the cells were differentiated for 3 days using RNeasy
Mini Kit (Quiagen, Hilden, Germany) according to the manufacturer’s
instruction.
First strand cDNA synthesis kit for RT–PCR (Roche Applied Science,
Vienna, Austria) was used for reverse transcription of 500ng RNA
(each sample) according to the manufacturer’s instructions.
q-PCR was performed using Taqman gene expression assays for myelin
basic protein (MBP) (ABI, Foster City, CA, USA, Rn 00566745_M1) and
b-2-microglobulin (b2-MG) (ABI, Rn 00560865). Three independent
experiments were conducted and all reactions were performed in tripli-
cate on a 7500 Fast Real-Time PCR System. Semi-quantitative mRNA
expression levels were calculated with the 7500 Fast System Software
(ABI, Foster City, CA).
Pharmacological inhibition of ROCK-II
and PKC
To examine whether ROCK-II and PKC signal transduction is impli-
cated in the myelin mediated differentiation block, pharmacological
inhibitors were added to the culture medium immediately after cell
seeding. The selective PKC-inhibitor Go ¨6976 speciﬁc for PKC- and
PKC-b (12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-
indolo[2,3-a]pyrrollo[3,4-c]carbazole; CAS-number: 136194-77-9)
and BIM (Ro 31-8220, Bisindolylmaleimide IX; CAS-number:
125314-64-9) selectively affecting all PKC isoforms were used to
block PKC-signalling. To inhibit ROCK-II, an orally available drug cur-
rently evaluated for the treatment of vascular disease named Fasudil
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1,4-diazepine 2 HCl; CAS-number: 103745-39-7) was used with the
potential of interfering with Rho kinase, PRK2, MSK1, PKA, PKG,
S6K1, MAPKAP-K1b, MLCK and CaMKII signalling. Go ¨6976 and
BIM were solubilized in DMSO. OPCs plated on different substrates
were differentiated for 48h and subsequently ﬁxed for immunocyto-
chemistry. To quantitate differentiation, the ratio of O4 positive cells
and the number of Hoechst-positive nuclei was determined by cell
counts using an Olympus IX 51 ﬂuorescence microscope. A minimum
of 200 cells were counted for each experiment and a minimum of
three independent experiments were conducted.
siRNA-based downregulation of
RhoA and PKC-a
Ten days after plating mixed glial cultures were transfected with
siRNA for PKC-, RhoA, negative control siRNA and Cy
TM3 labelled
negative control (Applied Biosystems) using Lipofectamine 2000
(Invitrogen, Paisley, UK) at a concentration of 100nM according to
the manufacturer’s protocol. Twenty-four hours later OPCs were
harvested as outlined above. To determine the knock-down efﬁciency
of the targeted genes Western blot analyses were performed for RhoA
(Millipore Corporation) or PKC- (Cell Signalling, Danvers, MA, USA).
OPC differentiation was assessed as outlined above 48h after plating
cells onto the experimental substrates; at least three independent
experiments were conducted for each condition.
TUNEL assay
Fragmented DNA was detected by incorporation of biotinylated
nucleotides at the 30-OH DNA ends using terminal deoxynucleotidyl
transferase recombinant (rTdT) enzyme according to the manufac-
turer’s instruction (Promega, Madison, WI, USA). Stained cells were
visualized by light microscopy and the percentage of apoptotic nuclei
was determined.
Western blot analysis
OPCs differentiated for 24h and 9 days on PLL were lysed in a
buffer containing 10mM Tris, pH 7.4, 100mM NaCl, 1mM EDTA,
1mM EGTA, 1mM NaF, 20mM Na4P2O7, 2mM Na3VO4,
0.1% SDS, 0.5% Sodium Deoxcholate, 1%Triton-X100, 10%
Glycerol, 1mM PMSF, 60mg/ml Aprotinin, 10mg/ml Leupeptin,
1mg/ml Pepstatin. After high speed centrifugation, protein concentra-
tion was measured using BCA
TM protein assay (Pierce) and 15mg were
loaded on SDS–PAGE for separation. Western blot was conducted
using a Multiphor II Electrophoresis System (GE Healthcare UK Ltd)
at 200mA for 1.30h. After blocking with 5% BSA in TBS-T (0.1% Triton
X 100 in TBS) for 1h at room temperature the blots were incubated with
antibodies against ROCK II/ROK (BD Biosciences, San Jose, CA, USA),
RhoA (Millipore Corporation) or PKC- (Cell Signalling) antibodies
over night (4 C). Following incubation with horseradish-peroxidase
conjugated secondary antibody (GE Healthcare UK Ltd) for 1h the
immunoreactive bands were detected by ECL
TM chemiluminescence
(GE Healthcare UK Ltd) reagent on a ﬁlm.
To conﬁrm the presence of proteins identiﬁed by MS analysis in the
puriﬁed inhibitory fractions, 10mg of protein was separated using 12%
Novex gel (Invitrogen). MPE was used as positive control and protein
extracts of liver membrane preparation as negative control. Following
SDS–PAGE, the protein was then transferred to PVDF membrane using
an Xcell II Blot Module (Invitrogen). After blocking with 5% BSA in
TBS-T (0.1% Triton X 100 in TBS) for 1h at room temperature it
was probed overnight at 4 C with the following antibodies: myelin-
associated glycoprotein (MAG) (Millipore Corporation), PLP (kindly
provided by Lees MB), MBP (DAKO). Following a wash step the
membranes were incubated with the appropriate horseradish-
peroxidase conjugated secondary antibody (GE Healthcare UK Ltd)
for 1h. The immunoreactive bands were detected by ECL
TM chemilu-
minescence (GE Healthcare UK Ltd) reagent on a ﬁlm.
Evaluation of Fyn activation
Cells were washed twice with ice cold PBS before being lysed in
10mM Tris, 100mM NaCl, 1mM EDTA, 1mM EGTA, 1mM NaF,
2mM Na 3VO4, 0.1% Triton, 10% Glycerol, 1mM PMSF, 0.5%
Na-Deoxycholate, 20mM Na4P2O7 and protease inhibitor (Roche).
Cell lysates were centrifuged (1h, 3200rpm, 4 C) and the protein
concentration was estimated by BCA
TM assay (Pierce). The lysates
were pre-cleared with A/G Plus Agarose beads (Santa Cruz, CA,
USA) for 30min at 4 C and incubated with total Fyn antibody
(Santa Cruz) for 2h in a rotary mixer following addition of A/G Plus
Agarose beads for overnight incubation. Before performing SDS–PAGE
and Western blot the immune complexes were washed extensively
with NP-40 buffer and PBS. The precipitates were re-suspended
in sample buffer, heated to 95 C for 5min, and subjected to
SDS–PAGE. Proteins were transferred to a PVDF membrane, blocked
with bovine serum albumin and incubated with Y-418-phospho-Src
(Biosource) antibody. Finally a horseradish-peroxidase conjugated
secondary antibody was added and detected by ECL
TM chemilumines-
cence (GE Healthcare UK Ltd) reagent on ﬁlm. The optical density
of the bands was estimated with NIH-Image J (free download at
http://rsb.info.nih.gov/ij/) on digitized images.
RhoA GTPase activity assay
For the detection of active RhoA, OPCs were lysed (125mM HEPES,
pH 7.5, 750mM NaCl, 5% Igepal CA-630, 50mM MgCl2,5 m M
EDTA, 10% Glycerol, 25mM NaF, 1mM Na3VO4) according to the
manufacturer’s instructions (Millipore Corporation) and active GTP-
Rho was precipitated by the use of beads speciﬁc for the GST-binding
domain (RBD) of rhotekin. After removing cell debris the lysates were
incubated with Rho Assay Reagent Slurry, which speciﬁcally binds
Rho-GTP and not Rho-GDP (30min, 4 C). Beads were then washed
with Mg
2+ lysis/wash buffer and bound material was eluted with 25ml
2  Laemmli sample buffer, boiled for 5min, resolved by SDS–PAGE
and immunoblotted using mouse anti-RhoA antibody (3mg/ml).
Peroxidase-conjugated anti-mouse IgGs (GE Healthcare UK Ltd)
were used as secondary antibodies. Immunoreactive proteins were
visualized using ECL
TM detection system (GE Healthcare UK Ltd).
Densitometric analysis was performed using NIH-Image J software.
Statistical analysis
For all studies at least three independent experiments (n as detailed in
results) were conducted and statistically assessed using Graph Pad
Prism software (Graph Pad, San Diego, CA). To test the concentration
dependent inhibition of OPC differentiation on MPE and the effect of
various concentrations of pharmacological inhibitors one way ANOVA
followed by Dunett’s multiple comparison test was used. ROD values
from Western blot following immunoprecipitation or pull-down assay
were compared with Student-t-test.
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Soluble myelin molecules inhibit
the differentiation of OPCs
To establish an in vitro assay for assessing the effects of myelin on
OPC differentiation we adapted an approach previously reported
by Robinson and Miller and plated neonatal OPCs on myelin
substrates produced by incubation of myelin preparations on
poly-L-lysine covered culture dishes (Robinson and Miller, 1999).
The differentiation of oligodendrocyte lineage cells (OLCs) in vitro
is characterized by distinct morphological and immunological fea-
tures. Antibodies against O4 identify late OPCs by reacting with a
sulphated glycolipid antigen named POA (Proligodendrocyte
Antigen), while the same antibody also recognizes terminally dif-
ferentiated OLCs by reacting with sulphated galactosylcerebroside
(Bansal et al., 1989). The differentiation block mediated by pres-
ence of myelin is manifested as a reduction in O4-expression by
OPCs (Robinson and Miller, 1999). In a previous study we showed
that MPEs prepared with n-octyl-glycoside induce a concentration-
dependent inhibition of differentiation in OPCs cultured in differ-
entiation medium for 48h similar to that observed with crude
myelin membrane preparations (Syed et al., 2008). The inhibition
of OPC differentiation is not only reﬂected by a reduction of O4
expression but also by a corresponding downregulation of mRNA
expression for MBP, a late marker of mature oligodendrocytes, as
assessed by qPCR (Fig. 1; n=3). The presence of myelin was
associated with a reduction in the complexity of OPC processes
resulting in an increase of early OPC phenotypes with bipolar
(stage I) morphology or primary branches (stage II) and a consec-
utive reduction of OPCs with secondary branched or membranous
processes (stage III/IV) (Fig. 6) (one-way ANOVA P50.0001). We
also conﬁrmed previous data (Robinson and Miller, 1999) demon-
strating that no changes occurred in the rate of cell proliferation as
assessed by BrdU staining (no BrdU-positive cells were detected in
the experimental groups) or apoptosis assessed by TUNEL assay,
indicating that differences in the proportion of O4-positive cells
reﬂect changes of cell differentiation and that these were not
caused by an increase of OPC proliferation or differences in the
rate of apoptosis (Supplementary Fig. 1).
Puriﬁcation of inhibitory myelin
fractions and proteomic analysis
The myelin proteins responsible for the inhibition of OPC differ-
entiation are unknown. The most prominent myelin associated
inhibitors (MAI) NogoA, MAG and Omgp do not affect OPC dif-
ferentiation (Syed et al., 2008). To identify potential candidates
we developed a column-chromatography fractionation protocol.
In the ﬁrst step MPE was submitted to a CM-column, and
the resulting fractions tested by plating OPCs on the eluates.
The fraction carrying inhibitory activity was then submitted to a
second puriﬁcation step using an ion exchange column (HighQ).
The eluates obtained were tested in the same manner and the
ﬁnal inhibitory fraction was used for proteomic analysis.
To identify the protein species contained in the inhibitory frac-
tion we employed a 3D gel-based separation protocol (BN-SDS-
SDS) speciﬁcally tailored for identiﬁcation of membrane-bound
proteins (Kang et al., 2008). The protein spots on the 12 resulting
gels were picked, digested and analysed on a nano-HPLC-ESI-Q-
TOF mass spectrometer. The proteins identiﬁed are presented in
Table 1 according to their annotation to the spots picked
(Supplementary Fig. 2A–F). Of the 137 proteins detected, 18
were previously identiﬁed in proteomic analyses of myelin mem-
brane fractions (Taylor and Pfeiffer, 2003; Taylor et al., 2004;
Vanrobaeys et al., 2005; Werner et al., 2007). To conﬁrm the
presence of selected protein species we conducted Western blots
on fractions generated as outlined above (Supplementary Fig. 3).
These data provide a list of potential candidates that may be
responsible for the inhibitory effect on OPC differentiation and
illustrate the complexity of the myelin proteome, which becomes
speciﬁcally apparent when highly abundant protein species are
removed by column-chromatography based separation techniques.
Myelin impairs activation of the Src
family tyrosine kinase Fyn-1
To investigate the basis of the myelin mediated inhibition of OPC
differentiation we examined the activation of Src family tyrosine
kinase Fyn-1. Several lines of evidence implicate an important role
for Fyn-1 in the formation of myelin sheaths: ﬁrst, the myelin
content found in brains of fyn-deﬁcient mice is reduced, and
Fig. 1 OPCs plated on MPEs (protein/cm
2) display a con-
centration dependent down-regulation of relative MBP mRNA
expression as assessed by qPCR after 3d culture in differenti-
ation medium (for this and subsequent ﬁgures: MPE: myelin
protein extract; error bars: SEM).
470 | Brain 2009: 132; 465–481 A. S. Baer et al.Table 1 Identiﬁed protein list from BN/SDS/SDS–PAGE (3DE) from puriﬁed myelin protein fraction
Protein Name Swiss-Prot
ID
NCBI
Acc. No
a
Theoretical
molecular
weight
No. of
TMD
b
Total
ion-score
No. of matched
peptides
(MS/MS)
Sequence
coverage
(%)
Spot
No.
Known myelin proteins
Myelin-associated glycoprotein precursor P07722 gi|126685 69353 1 294 8 21 18
Myelin basic protein S P02688 gi|17378709 21546 0 36 1 5 131
Myelin-oligodendrocyte glycoprotein precursor Q63345 gi|2497314 27882 2 112 3 13 77
Myelin proteolipid protein P60203 gi|41019153 30077 4 124 3 18 3
Membrane proteins
Abhydrolase domain-containing protein 6 Q5XI64 gi|81883706 38312 1 155 4 13 89
Acyl-CoA-binding domain-containing protein 5 A0FKI7 gi|123797828 56782 1 59 1 4 58
Basigin precursor P26453 gi|51704207 42436 1 89 2 5 117
Brain acid soluble protein 1 Q05175 gi|730110 21790 0 321 10 41 17
CD9 antigen P40241 gi|729088 25215 4 239 7 32 2
CD63 antigen P28648 gi|113331 25699 4 79 2 11 101
CD81 antigen Q62745 gi|11131474 25889 4 211 5 16 4
CD82 antigen O70352 gi|9296930 29487 4 45 2 10 21
CD151 antigen Q9QZA6 gi|11131479 28355 4 160 4 20 51
CD166 antigen precursor O35112 gi|47605356 21635 1 194 6 29 74
Cell adhesion molecule 2 precursor Q1WIM2 gi|150438865 47528 1 194 4 11 53
Cell adhesion molecule 4 precursor Q1WIM1 gi|123778954 42781 1 193 6 15 28
Cell cycle exit and neuronal differentiation protein 1 Q5FVI4 gi|81882797 15043 1 88 3 23 44
Choline transporter-like protein 1 Q8VII6 gi|73918925 73092 10 61 3 4 27
Clathrin coat assembly protein AP180 Q05140 gi|2492686 93519 0 96 3 3 92
Claudin-11 Q99P82 gi|20532024 22046 4 189 6 37 45
Disks large-associated protein 2 P97837 gi|71153508 118978 0 164 6 8 34
DnaJ homolog subfamily C member 5 P60905 gi|46397406 22101 0 42 2 11 50
Ectonucleotide pyrophosphatase/phosphodiesterase family member 5 precursor P84039 gi|108862048 54290 1 164 5 12 71
Embigin precursor O88775 gi|61223483 37005 1 176 5 23 72
Erythropoietin receptor precursor Q07303 gi|729431 55500 1 88 4 6 94
FXYD domain-containing ion transport regulator 6 precursor Q91XV6 gi|20138106 10388 1 229 7 26 63
FXYD domain-containing ion transport regulator 7 P59649 gi|30315809 8487 1 38 1 19 5
Golgin subfamily A member 2 Q62839 gi|6226622 111428 0 106 3 4 14
Junctional adhesion molecule C precursor Q68FQ2 gi|83286894 34783 1 168 5 16 38
Leukocyte surface antigen CD47 precursor P97829 gi|76364105 32995 5 69 3 14 33
Limbic system-associated membrane protein precursor Q62813 gi|2497324 37324 0 114 2 7 26
Lysosome-associated membrane glycoprotein 1 precursor P14562 gi|126378 43969 1 225 5 11 16
Lysosome-associated membrane glycoprotein 2 precursor P17046 gi|126382 45591 1 203 6 17 136
Lysosome membrane protein 2 P27615 gi|126291 54091 2 268 12 33 22
Major prion protein precursor P13852 gi|2507236 27804 0 33 1 7 49
Membrane transport protein XK Q5GH61 gi|77417634 51050 10 133 4 10 23
Metabotropic glutamate receptor 4 precursor P31423 gi|400255 101819 7 39 2 1 121
Myosin-9 Q62812 gi|13431671 226338 0 108 4 2 102
Neural cell adhesion molecule 1, 140kDa isoform precursor P13596 gi|127859 94658 1 203 5 6 115
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Protein Name Swiss-Prot
ID
NCBI
Acc. No
a
Theoretical
molecular
weight
No. of
TMD
b
Total
ion-score
No. of matched
peptides
(MS/MS)
Sequence
coverage
(%)
Spot
No.
Neuroﬁlament medium polypeptide P12839 gi|128150 95791 0 110 4 6 128
Neuromodulin P07936 gi|128102 23603 0 116 3 14 110
Neuroplastin precursor P97546 gi|81870588 31292 1 278 7 36 19
Neurotrimin precursor Q62718 gi|2497325 37998 0 44 2 7 39
Nicastrin precursor Q8CGU6 gi|37081094 78400 1 332 12 32 15
Neuritin precursor O08957 gi|81882120 15289 0 103 3 10 66
Nuclear envelope pore membrane protein POM 121 P52591 gi|1709213 120785 1 226 5 4 80
Opioid-binding protein/cell adhesion molecule precursor P32736 gi|1352640 38068 0 138 3 11 25
Phosphatidylethanolamine-binding protein 1 P31044 gi|400734 20801 0 154 5 21 62
Phospholemman precursor O08589 gi|22654268 10365 1 100 3 19 60
Prostaglandin-H2 D-isomerase precursor P22057 gi|1346697 21301 0 201 4 16 137
Protocadherin Fat 2 precursor O88277 gi|22095688 480654 1 119 3 6 57
Sodium channel protein type 9 subunit alpha O08562 gi|55976160 226039 24 144 5 2 83
Sodium channel subunit beta-2 precursor P54900 gi|1705870 24145 1 121 4 19 36
Sodium/potassium-transporting ATPase subunit beta-1 P07340 gi|114395 35202 1 88 3 7 56
Synaptosomal-associated protein 23 O70377 gi|41017815 23235 0 79 2 9 65
Synaptosomal-associated protein 25 P60881 gi|46397720 23315 0 114 3 8 67
Syntaxin-1B P61265 gi|47117736 33245 1 188 6 17 64
Tetraspanin-2 Q9JJW1 gi|23396887 24190 4 63 2 8 29
Thioredoxin domain-containing protein C5orf14 homolog Q5BJT4 gi|81882519 37928 1 205 5 8 107
Tyrosine-protein phosphatase non-receptor type substrate 1 precursor P97710 gi|29427383 55691 1 105 4 10 122
Thy-1 membrane glycoprotein precursor P01830 gi|135832 18172 0 99 3 11 130
Voltage-dependent anion-selective channel protein 2 P81155 gi|46397780 31746 0 133 5 14 37
20,30-cyclic-nucleotide 30-phosphodiesterase P13233 gi|51338709 47268 0 319 6 13 7
Cytoplasmic proteins
Amphiphysin O08838 gi|14916529 74878 0 118 3 5 114
Branched-chain-amino-acid aminotransferase, cytosolic P54690 gi|1705438 46046 0 226 7 24 98
Calmodulin P62161 gi|49037408 16838 0 125 3 16 111
Coiled-coil domain-containing protein 93 Q5BJT7 gi|81882521 72636 0 152 4 6 104
COP9 signalosome complex subunit 1 P97834 gi|2494624 53428 0 108 4 9 24
ERC protein 2 Q8K3M6 gi|51701368 110618 0 98 2 3 42
FKBP12-rapamycin complex-associated protein P42346 gi|1169736 288794 0 68 2 1 87
Glial ﬁbrillary acidic protein P47819 gi|115311597 49957 0 113 3 10 31
Glutathione transferase omega-1 Q9Z339 gi|12585231 27669 0 113 3 9 106
Heat shock cognate 71kDa protein P63018 gi|51702273 70871 0 271 5 6 135
Huntingtin P51111 gi|1708162 343762 0 101 3 1 91
Hypoxanthine-guanine phosphoribosyltransferase P27605 gi|123501 24477 0 32 1 4 124
Junction plakoglobin Q6P0K8 gi|81885083 81801 0 105 4 5 41
LAMA-like protein 2 precursor Q4QQW8 gi|146324959 65456 0 201 5 9 90
Myc box-dependent-interacting protein 1 O08839 gi|14916534 64533 0 229 8 12 113
NAD-dependent deacetylase sirtuin-2 Q5RJQ4 gi|81883338 39319 0 91 2 5 109
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.Neurocalcin-delta Q5PQN0 gi|81909955 22245 0 126 4 20 61
Neuron-speciﬁc calcium-binding protein hippocalcin P84076 gi|51317364 22427 0 98 4 23 59
glycosyltransferase GLT28D1 Q5I0K7 gi|81883003 18329 0 62 2 7 69
Phenylalanyl-tRNA synthetase alpha chain Q505J8 gi|81887353 57720 0 88 2 5 118
Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Q9JMC1 gi|30315961 107208 0 97 4 3 88
Protein kinase C and casein kinase substrate in neurons protein 1 Q9Z0W5 gi|22256946 50449 0 114 5 14 116
Protein S100-A3 P62819 gi|51338664 11747 0 52 1 14 12
Protein S100-A6 P05964 gi|46397773 10035 0 89 2 28 11
Protein S100-B P04631 gi|134139 10744 0 98 3 18 68
Superoxide dismutase [Cu-Zn] P07632 gi|134625 15912 0 106 2 13 55
Thioredoxin P11232 gi|135776 11673 0 135 4 24 1
Tropomyosin alpha-1 chain P04692 gi|92090646 32681 0 88 2 6 76
Tropomyosin alpha-3 chain Q63610 gi|148840439 29007 0 76 2 7 75
Ubiquitin carboxyl-terminal hydrolase 19 Q6J1Y9 gi|81863791 150302 0 119 6 3 99
UDP-glucose:glycoprotein glucosyltransferase 1 precursor Q9JLA3 gi|68052986 174049 0 157 3 2 81
Visinin-like protein 1 P62762 gi|51338688 22142 0 213 6 31 78
14-3-3 protein zeta/delta P63102 gi|52000883 27771 0 228 7 28 54
Nuclear proteins
Calpain-5 Q8R4C0 gi|28376969 73065 0 155 5 10 96
Cell division cycle 5-related protein O08837 gi|73619939 92218 0 33 3 3 79
DNA repair protein RAD50 Q9JIL8 gi|60392975 153784 0 223 5 3 125
Histone H2B type 1 Q00715 gi|399856 13990 0 123 3 21 8
Histone H2B type 1-A Q00729 gi|399855 14225 0 109 2 26 9
Histone H3.1 Q6LED0 gi|81863898 15404 0 49 1 8 13
Histone H4 P62804 gi|51317315 11367 0 102 3 34 10
La-related protein 7 Q5XI01 gi|134034153 64949 0 32 3 10 129
RING ﬁnger protein 181 Q6AXU4 gi|81891326 19288 0 34 2 9 119
Small ubiquitin-related modiﬁer 2 precursor P61959 gi|48429128 10871 0 76 3 13 108
Structural maintenance of chromosomes protein 3 P97690 gi|29336525 138448 0 149 4 3 82
UV excision repair protein RAD23 homolog B Q4KMA2 gi|123789085 43497 0 133 4 7 112
Vimentin P31000 gi|401365 53733 0 251 6 14 103
Zinc ﬁnger CCCH type antiviral protein 1 Q8K3Y6 gi|47117346 86771 0 100 4 7 84
Secreted proteins
Alpha-1-antiproteinase precursor P17475 gi|112889 46136 0 164 5 19 97
Apolipoprotein D precursor P23593 gi|114035 21635 0 162 5 25 47
C-reactive protein precursor P48199 gi|1345834 25468 0 65 3 17 20
Serine protease inhibitor A3K precursor P05545 gi|266407 46562 0 211 6 16 85
Serine protease inhibitor A3L precursor P05544 gi|2507387 46277 0 206 5 16 86
Sulfated glycoprotein 1 precursor P10960 gi|134219 61124 0 264 5 10 6
Transthyretin precursor P02767 gi|136467 15720 0 76 2 10 134
Extracellular proteins
Annexin A8 Q4FZU6 gi|123792388 36706 0 151 4 15 52
Hemoglobin subunit alpha-1/2 P01946 gi|122477 15329 0 255 7 39 48
Hemoglobin subunit beta-1 P02091 gi|122514 16083 0 245 8 36 46
Lysosomal proteins
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3second, Fyn-1 can be co-immuno-precipitated from brain lysates
with antibodies to MAG (Umemori et al., 1994). More recent data
suggest that activation of Fyn-1 is one of the earliest events
triggered in differentiating OPCs and that Fyn-1 tyrosine kinase
regulates process extension and myelin sheath formation
(Osterhout et al., 1999; Colognato et al., 2004).
Protein extracts from OPCs plated on MPE cultured in differen-
tiation medium for 24h were compared with protein extracts from
OPCs plated on control substrates under the same conditions by
immuno-precipitation with anti-Fyn-1 and immunoblotting with
anti-Src Y-418, to detect phosphorylation at the activation site
of Fyn-1. The results demonstrated a clear impairment of Fyn-1
activation in cells plated on MPE (n=4; t-test P=0.0003; Fig. 2A
and B). In OPCs plated on control substrate phosphorylation of
Fyn-1 increased over time as previously reported (Osterhout et al.,
1999).
Myelin molecules mediate inhibitory
signals via activation of RhoA
Fyn-1 kinase regulates the activity of the small GTPase RhoA
(Colognato et al., 2004), which, along with other Rho GTPase
subfamily members is an important regulator of oligodendrocyte
morphology (Mi et al., 2005; Thurnherr et al., 2006). Over-
expression of dominant-negative RhoA causes hyperextension of
oligodendrocyte processes (Wolf et al., 2001) while a reduction of
active RhoA-GTP is necessary for successful oligodendrocyte dif-
ferentiation (Liang et al., 2004). To assess activation of RhoA in
OPCs cultured on MPE and control substrates for 24h in differ-
entiation medium we performed a RhoA-GTP-pull down assay
followed by Western blot for RhoA. Our data show that the pres-
ence of myelin inhibitors induces an increase of GTP bound RhoA
(n=3; t-test: P=0.0113; Fig. 2C and D).
To assess the functional role of RhoA in mediating inhibitory
effects of MAI to OPC differentiation we transfected OPCs with
siRNA speciﬁcally directed against RhoA. Cells were transfected
with high efﬁciency (495%). This induced a marked down-regula-
tion of the expression of RhoA as assessed by Western blot. The
reduction of RhoA powerfully triggered OPC differentiation in the
presence of MPE (Fig. 5; n=3; mean increase=233%; ANOVA:
P50.0001, Dunnett’s post-test MPE versus siRNA: P50.0001)
conﬁrming the importance of RhoA in mediating the inhibitory
effects as well as indicating that these can be beneﬁcially modu-
lated by inhibiting RhoA signalling in OPCs.
Inhibition of ROCK-II induces
differentiation of OPCs in the
presence of myelin
Rho kinases (ROCK) are important effector proteins of RhoA and
phosphorylate a number of downstream molecules that regulate
actin ﬁlaments (Riento and Ridley, 2003). Since ROCK-II is the
isoform predominantly expressed in the CNS, we hypothesized
its participation in transducing myelin derived inhibitory signals in
OPCs. We ﬁrst conﬁrmed ROCK-II expression in OPCs
by Western blot analysis and then examined its functional role
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474 | Brain 2009: 132; 465–481 A. S. Baer et al.by plating OPCs on MPE and adding different concentrations of
the ROK/ROCK II-inhibitor HA-1077 (Fasudil) to the differenti-
ation medium (Fig. 3). Treatment with HA-1077 for 48h resulted
in a dramatic increase in the number of differentiating OPCs
(n=4; mean increase at 5mM=174%; ANOVA: P50.0001,
Dunnett’s post tests MPE versus 5 and 10mM: P50.001). To
exclude changes in cell survival we conducted TUNEL assays
which showed no signiﬁcant differences between OPCs plated
on PLL and cells plated on MPE treated with HA-1077
(Supplementary Fig. 1).
Thus, we conclude that RhoA-ROCK signalling plays an
important role in mediating myelin derived inhibitory effects
in differentiating OPCs that can be beneﬁcially modulated by
the use of pharmacological inhibitors and siRNA-mediated gene
silencing.
Myelin inhibitors retain Myristoylated,
alanine-rich C-kinase substrate within
the cytosolic compartment
PKC has also been implicated in OPC differentiation since PKC
activation mimicked by the phorbol ester PMA inhibits OPC dif-
ferentiation (Baron et al., 1998) while at late stages of OPC dif-
ferentiation, PKC may also facilitate process extension and
expression of myelin proteins (Althaus et al., 1991; Yong et al.,
1991; Asotra and Macklin, 1993; Stariha and Kim, 2001).
Myristoylated, alanine-rich C-kinase substrate (MARCKS) is a sub-
strate of PKC that has been used as an indirect marker for PKC
activation in OPCs (Baron et al., 1999). Inhibitory PKC mediated
signalling is associated with phosphorylation and membrane-to-
cytosol translocation of MARCKS (Baron et al., 1999) and may
cause disorganization of the cytoskeleton and redistribution of
actin ﬁlaments (Baron et al., 1998, 1999). MARCKS has been
implicated in several cellular processes such as secretion, phago-
cytosis, cell motility, membrane trafﬁc, growth suppression and
regulation of the cell cycle as well as OPC differentiation (Baron
et al., 1998, 1999; Arbuzova et al., 2002). Phosphorylated
MARCKS is translocated from the plasma membrane to the cyto-
sol (Wang et al., 1989; Thelen et al., 1991; Byers et al., 1993;
Allen and Aderem, 1995). To detect changes in the intracellular
distribution of MARCKS OPCs plated on MPE and control-PLL
stained for A2B5 and MARCKS were compared using a laser scan-
ning microscope (Fig. 4A–F). In differentiating OPCs MARCKS
was distributed to the cell membrane whereas in OPCs in which
differentiation was inhibited by the presence of MPE a clear cyto-
solic presence of MARCKS was detected supporting the notion
that PKC is activated by myelin and that myelin inhibitors modu-
late cytoskeletal dynamics by MARCKS.
Fig. 2 (A) Myelin inhibitors impair Fyn-1/Y-418 phosphorylation in OPCs, (B) immunoblot following anti-Fyn-1-immunoprecipitation
and loading control. (C) Myelin inhibitors also induce activation of RhoA. (D) Autoradiograph of Rho assay (MPE: 40mg/cm
2;
PLL: poly-L-lysine; incubation in differentiation medium for 24h).
Fig. 3 (A) Immunoblot of OPC lysates demonstrates that differentiating OPCs express ROCK-II. (B) Inhibition of ROCK-II by culturing
OPCs on MPE with Fasudil (HA-1077) results in a more than 160% increase of differentiating cells after 48h culture in differentiation
medium. (C) Whereas OPCs on MPE down-regulate O4 immunoreactivity. (D) O4 expression is largely restored by treatment with
HA-1077 (scale bar=30mM).
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differentiation in the presence of
myelin inhibitors
In order to test whether inhibition of PKC signalling is able to
modulate the myelin-mediated differentiation block OPCs plated
on myelin were treated with the two selective PKC inhibitors, BIM
(Bisindolylmaleimide IX, Methasulfonate Salt) and Go ¨6976.
We found that treatment with BIM (n=4; mean increase at
6.25nM=169%; ANOVA: P50.0001, Dunnett’s post tests MPE
versus 6.25nM: P50.001; 12.5nM: P50.05) and even more so
with Go ¨6976 (n=3; mean increase at 50nM=267%; ANOVA:
P50.0001, Dunnett’s post-test MPE versus 25nM: P50.05;
Fig. 4 (A–F) MARCKS is a down-stream effector of PKC. While in control cells MARCKS expression is associated with the cell
membrane, myelin inhibitors lead to a cytoplasmatic MARCKS presence. (G–N) Inhibition of PKC signaling in OPCs on MPE with BIM
(G–J; max. mean increase 169%) or Go ¨6976 (K–N; max. mean increase 269%) strongly induces OPC differentiation after 48h
incubation in differentiation medium. (Scalebar: in A–C: 15.9mm, in D–F: 14.6mmi nH–J, L–N:3 0 mm).
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presence of myelin (Fig. 4G–N). TUNEL assays showed no differ-
ences in the rate of apoptosis between control cells and OPCs
plated on myelin treated with Bim or Go ¨-6976 (Supplementary
Fig. 1). As the use of pharmacological inhibitors entails the risk
of regulating cascades other than the targeted, we used siRNA to
down-regulate PKC- expression in OPCs plated on myelin
(Fig. 5). SiRNA-mediated silencing of PKC- was successful and
cells transfected displayed a marked decrease of PKC- at protein
level. The reduction of PKC- potently induced OPC differentia-
tion on MPE conﬁrming the validity of the pharmacological
approach (n=3; mean increase = 232%; ANOVA: P50.0001,
Dunnett’s post test MPE versus siRNA: P50.0001) (Fig. 5).
Blocking both ROCK-II and PKC further
promotes OPC differentiation
We next investigated whether ROCK-II and PKC transduce inhib-
itory signals via common or separate mechanisms and whether
blocking both pathways at the same time could further promote
OPC differentiation in the presence of myelin inhibitors. Treatment
with Fasudil and Go ¨6976 simultaneously induced a further
increase of the percentage of differentiating OPCs (Fig. 6; t-test:
HA-1077 versus co-incubation: P=0.0009; Go ¨6976 versus
co-incubation: P=0.0288). Furthermore, the treatment of OPCs
on MPE with the inhibitors was able to reverse the effects
of myelin on OPC morphology and resulted in the presence of
more mature phenotypes (stages III and IV, Fig. 6; ANOVA of
early stages (I/II) in PLL, MPE, and co-treatment P=0.0027;
Dunn post-test: MPE versus co-treatment P50.01). MPE may
not include all inhibitory factors present in crude myelin prepara-
tions. To ensure that the beneﬁcial treatment effects were not
restricted to substrates prepared with MPE we incubated OPCs
plated on crude myelin preparations with HA-1077, Go ¨6976,
or a combination of both. This resulted in a similar induction of
OPC differentiation in the presence of myelin inhibitors (data not
shown). Taken together our ﬁndings suggest that the inhibitory
effects of myelin molecules are mediated by at least two indepen-
dent pathways. Furthermore, blocking both pathways simulta-
neously may provide an even more potent strategy to improve
OPC differentiation in an in vivo setting.
Discussion
Axonal integrity is tightly coupled with myelin function as subtle
changes in the molecular composition can result in mid- to long
term axonal degeneration under otherwise physiological conditions
(Grifﬁths et al., 1998; Garbern et al., 2002; Lappe-Siefke et al.,
Fig. 5 (A and B) Transfection efﬁciency of OPCs was monitored by transfecting cells with RNAi (cy-3) and assessing the proportion of
cy-3-labelled cells after 48h in differentiation medium (n=3); in all experiments495% of the cells were cy-3 positive. Immunoblots of
OPC lysates after transfection with (C) RNAi for RhoA as well as (D) RNAi for PKC- demonstrate downregulation of RhoA or PKC-
on protein level after 48h. (D) Silencing of RhoA or PKC- results in a signiﬁcant increase of O4 positive cells when cultured for 48h on
MPE. (F) Whereas transfection with control RNAi (RNAi(scrambled, scr)) was not able to restore O4-immuroreactivity of OPCs on
MPE (G and H) gene silencing induced a strong increase in the number of differentiating cells (scalebar=30mM).
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sheaths is also very likely to be of signiﬁcance for maintaining
axonal integrity in both acute and chronic CNS pathology, a situ-
ation in which denuded axons may be more prone to injury or
degeneration than axons bearing functionally intact myelin
sheaths. Thus increasing efforts have been placed in the develop-
ment of strategies by which remyelination may be enhanced ther-
apeutically (Dubois-Dalcq et al., 2005). Although much is known
about the biology of OPCs attempts to stimulate remyelination
in vivo by increasing or modulating the expression proliferation
or differentiation inducing factors have not been universally suc-
cessful, especially when older adult animals are used in which
myelin debris clearance is poor and remyelination inefﬁcient
(Shields et al., 1999; O’Leary et al., 2002; Sim et al., 2002;
Penderis et al., 2003; Ibanez et al., 2004; Woodruff et al.,
2004). The presence of inhibitory molecules in myelin debris gen-
erated as a consequence of oligodendrocyte degeneration may in
part provide an explanation for the so far generally frustrating
failure of these different strategies (Kotter et al., 2006).
The key aim of our study was to examine the mechanisms that
control the myelin mediated inhibition of OPC differentiation. The
myelin molecules blocking OPC differentiation remain unknown.
However, it is a plausible hypothesis that these molecules
expressed on mature oligodendrocytes provide a feed-back inhibi-
tion for early (A2B5+) precursor cells. Under normal physiological
situations this feed-back system may serve to prevent inappropri-
ate differentiation of OPCs in normal adult white matter
(Robinson and Miller, 1999), while in development one might
speculate that signalling from mature oligodendrocytes to early
precursors may play a functional role in regulating OPC differen-
tiation. The situation following demyelination entails profound
environmental changes as large amounts of degenerated myelin
can accumulate within lesions. In experimental models this is efﬁ-
ciently cleared by macrophages of microglial and monocytic origin
(Kotter et al., 2001, 2005). However, it is conceivable that if
clearance of myelin debris is disturbed by alterations of the inﬂam-
matory response the presence of myelin debris can persist and
thus for a prolonged period inhibit myelin repair. Recent studies
suggest that remyelination requires the signalling environment
provided by an acute inﬂammatory response (Mason et al.,
2001; Foote and Blakemore, 2005; Kotter et al., 2005; Setzu
et al., 2006). Therefore, it could be speculated that a situation
may occur in which the initial inclination OPCs to differentiate is
inhibited by the presence of myelin and turns into reluctance as
the expression of signalling molecules required to activate OPCs
diminishes.
The cascades that we found to be modulated by the presence of
myelin inhibitors are similar to the ones that regulate the inhibition
of axon growth via NogoR and Lingo-1 signalling (Lee et al.,
2004; Mi et al., 2005). However, there is no evidence that
Fig. 6 (A–C) Blocking PKC and ROCK-II simultaneously in OPCs plated on myelin by co-incubation with HA-1077 and Go ¨6976
induces an additional increase in the percentage of O4-positive cells as compared to single treatment after incubation in differentiation
medium for 48h. (B) While MPE induces down-regulation of O4 immunoreactivity in OPCs (C: the same cells stained for A2B5),
(D) O4 expression is restored after treatment with the pharmacological inhibitors. (E–G) The presence of MPE is associated with a
reduction of the complexity of OPC processes and earlier morphological stages as compared to OPCs plated on control substrate.
(H) Treatment with HA-1077 and Go ¨6976 restores the presence of more mature phenotypes (scalebar=30mM).
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detect NogoR expression in our cultures. While immunocytochem-
istry for Lingo-1 is inconclusive we found evidence of Lingo-1
mRNA in cultured OPCs (unpublished data). Furthermore, we
have not seen evidence of an inhibitory effect of any of the clas-
sical myelin inhibitors of axon growth on OPC differentiation
(Syed et al., 2008). Thus the molecular substrate present in
myelin mediating the inhibitory effects remains unknown.
In this study, we developed a biochemical and proteomic pro-
tocol to identify potential candidates responsible for the myelin
differentiation block. With the criteria we applied this resulted in
a list of 137 myelin proteins—18 of which were previously identi-
ﬁed using a proteomic approach. The detection of so many pre-
viously unidentiﬁed proteins in myelin can be explained in part
by the biochemical separation process we developed, which
removes many of the most abundant proteins. On the other
hand, we applied a gel-based separation technique that is specif-
ically tailored for the study of membrane-bound proteins that has
not been previously used for the analysis of the myelin proteome.
To identify the myelin protein(s) responsible for the inhibition of
OPC differentiation further separation steps may be helpful.
However, stringent data assessment may help to narrow down
the list of potential candidates. Apart from providing a list of
potential candidates our data illustrates the complexity of myelin
and will provide a reference for further studies of the biology of
myelin membranes.
Our results provide a model of how myelin exerts inhibitory
effects on OPC differentiation. In inhibiting RhoA-ROCK and
PKC(-) signalling we have identiﬁed pharmacological targets by
which OPC differentiation can be powerfully stimulated in the
context of myelin inhibitors.
Fasudil is currently evaluated in a clinical setting for treatment of
vasospasm as well as angina pectoris in humans (Vicari et al.,
2005). Similarly, a number of clinical studies investigate the effects
of PKC inhibitors in cancer (Mackay and Twelves, 2007). While it
has to be expected that not all inhibitors can pass the brain blood
barrier, a number of PKC inhibitors (e.g. Tamoxifen, Calphostin-C,
HA-1004 and Ro 32-0432) (Gozal et al., 1998; Cerezo et al.,
2002; Zarate et al., 2007) as well as Rho-cascade inhibitors
(e.g. Fasudil) are able to cross the brain blood barrier (Satoh
et al., 2008).
PKC and ROCK inhibition have shown to exert stimulating
effects on neurite outgrowth in the presence of myelin inhibitors,
and thus synergistic effects with respect to neural repair could be
expected (Sivasankaran et al., 2004). As far as effects on other cell
types are concerned, inhibition of PKC in microglia is associated
with e.g. downregulation of MHC-II (Nikodemova et al., 2007), a
reduction of proinﬂammatory cytokine, iNOS (Kang et al., 2001;
Min et al., 2004), and TNF- release (Jeohn et al., 2002) in
response to various inﬂammatory modulators including LPS, gan-
glioside and IFN suggesting a reduction of proinﬂammatory
activity in microglia. On the other hand, it has been reported
that PKC inhibition lead to reduced CR3/Mac-1 and SRAI/II
mediated myelin phagocytosis (Cohen et al., 2006) which may
be relevant to myelin repair although the mechanisms we report
aim at neutralizing the effects of MAI on OPC differentiation.
Astrocytes react upon PKC inhibition by e.g. decreased activa-
tion of ATP-mediated glutamate outwards channels (Rudkouskaya
et al., 2008) and TGFb1 production (Wang et al., 2003), further-
more, the response to LPA is altered by a reduced proproliferative
intracellular Ca2+ increase (Keller et al., 1997) and NGF secretion
(Furukawa et al., 2007). It is difﬁcult to interpret these ﬁndings
in the light of remyelination as little is known about the molecular
events in astrocytes during myelin repair. However, it seems
unlikely that the effects of PKC inhibition on astrocytes reported
will negatively impact remyelination.
Under the inﬂuence of Fasudil rat astrocytes transform in vitro
into process bearing cells (Abe and Misawa, 2003) which can be
explained by direct effects of the Rho-cascade on the cytoskele-
ton, on the other hand there are no data available how changes in
astrocyte processes impact myelin repair.
Finally, little is known of how microglia react to inhibition of
the Rho-cascade. A recent paper suggests that inhibition of
RhoA by C3 induces NO and proinﬂammatory cytokine release,
however, this is independent of ROCK signalling and was instead
found to be under the control of NFkappaB suggesting that tar-
geting down-stream signalling events may circumvent problems
that may arise as a consequence of microglia activation
(Hoffmann et al., 2008).
Our data suggest that inhibiting PKC and/or Rho-signalling
would be beneﬁcial either acutely following demyelination,
where exposure to myelin debris that has yet to be cleared
might critically interrupt the initiation of remyelination resulting
in its long term failure or in chronic disease where OPCs remain
exposed to a differentiation-inhibitory environment. The data in
the current study paves the way for subsequent testing of phar-
macological interventions in animal models and further clinical
evaluation if the outcome were to be successful.
Supplementary material
Supplementary material is available at Brain online.
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